[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-type2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-type2":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,78,111,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100409100","intermittent-fasting-to-improve-insulin-secretion-100409100",false,"NCT04607096","Intermittent Fasting to Improve Insulin Secretion","IFIS","Inclusion Criteria:\n\n* Body mass index (BMI) between 25 - 40 kg\u002Fm²\n* Understand and voluntarily sign an informed consent document prior to any study related assessments\u002Fprocedures.\n* Subjects with prediabetes (IFG and\u002For IGT, HbA1c 5,4 % - 6,4 %, subphenotype cluster 3 or 5) or\n* Subjects with type 2 diabetes mellitus (diagnosed \\\u003C5 years prior to screening), HbA1c 6.0% - 9.5%, not receiving insulin or thiazolidinediones, and with an appropriate washout period for all other antidiabetic medications)\n\nExclusion Criteria:\n\n* Subjects with diabetes mellitus type 1 (GAD-, IA2-AB positive)\n* Women during pregnancy and lactation\n* Treamtent with any medication effecting on glucose metabolism like anti-diabetic drugs or steroids\n* Subjects with a haemoglobin (Hb) ≤ 11.5 g\u002Fdl (for males) and Hb ≤ 10.5 g\u002Fdl (for females) at screening\n* Any pancreatic disease\n* Medical history of cancer and\u002For treatment for cancer within the last 5 years.\n* Known current presence or history of severe neurological or psychiatric diseases, schizophrenia, bipolar disorder\n* Known history of bariatric surgery\n* Severe liver or kidney diseases (Alanine Aminotransferase (ALT \\[SGPT\\]), Aspartate Aminotransferase (AST \\[SGOT\\]) above 3 x upper limit of normal (ULN) or Glomerular Filtration Rate (eGFR) ≤ 60 ml\u002Fmin (MDRD formula)\n* Systemic infection (CRP \\> 1 mg\u002Fdl)\n* Severe diabetic complications like chronic kidney disease (CKD), proliferating retinopathy or symptomatic cardiovascular disease\n* Presence of any contraindication for the conduct of an MRI investigation, such as cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system, metallic splinters in the eye, ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators, cochlear implants, insulin pumps and nerve stimulators, prosthetic heart valves etc.\n* Persons with limited temperature sensation and \u002F or elevated sensitivity to warming of the body\n* Persons with a hearing disorder or a increased sensitivity for loud noises\n* Claustrophobia\n* Participation in other clinical trials or observation period of competing trials up to 30 days prior to this study\n* Refusal to get informed of unexpected detected pathological findings","ALL","18 Years","70 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","Type 2 diabetes (T2D) mellitus is a challenge for health care systems as the numbers increases constantly. In 2014, 422 million people had been living with diabetes worldwide. The absolute numbers of people with prediabetes have also grown substantially over 25 years worldwide. In Germany, about 10% of the population has T2D and another 21 % of the population has prediabetes.Overall, 16% of all deaths in Germany are attributable to type 2 diabetes. Macro- and microvascular complications of diabetes imply a significant threat for the patients and are already present in the prediabetic state. Short term and long term complications, the burden of treatment, and reduced quality of life are major burdens of the disease. Accumulating data indicate that currently recommended therapeutic diet regimens in patients with obesity and diabetes are not sustainable on the long term. Novel concepts are therefore urgently needed.\n\nT2D occurs when insulin secretion from pancreatic beta-cells cannot sufficiently be increased to compensate for insulin resistance. Causes of beta-cell dysfunction are heterogeneous. In addition, the most important determinants of diabetes remission are the extend of weight loss and restoration of beta-cell function. In the course of diabetes progression, the inability to recover insulin secretion might identify the state of no return to normal glucose tolerance. It is therefore crucial to improve insulin secretion in treatment and prevention of diabetes. Up to now lifestyle intervention trials in prediabetes or pharmacological intervention trials in diabetes did not show improvement of insulin secretion after intervention. However, one recent small human trial shows that intermittent fasting (early time restricted fasting) is able to improve insulin secretion.Currently, there are no trials that examine the effect of intermittent fasting in individuals with a broad range of impaired glucose metabolism (from prediabetes to diabetes). Recently novel subtypes of diabetes and prediabetes with high risk for the early manifestation of diabetes complications have been identified. Currently, prevention strategies for this high risk individuals have not been examined yet. We will study for the first time the effectiveness of 4 weeks intermittent fasting on changes in insulin secretion capacity in subphenotypes of diabetes and in prediabetes.",[27,28,29,30],"PreDiabetes","Diabetes type2","Intermittent Fasting","Insulin Secretion","RECRUITING","2026-04-20",{"date":34,"type":35},"2026-04-21","ACTUAL",{"date":37,"type":35},"2021-04-08",{"date":39,"type":21},"2027-03-01",{"name":41,"class":42},"University Hospital Tuebingen","OTHER",8,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100432824","diabetic-nephropathy-in-people-with-diabetes-prevalence-and-predictive-factors-100432824","NCT04916132","Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors","Biopsy-proven Diabetic Nephropathy in People With Type 2 Diabetes. Prevalence and Predictive Factors","PRIMETIME2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Diagnosis with T2DM according to the American diabetes Association (20)\n* eGFR \\>30 mL\u002Fmin\u002F1.73 m2 (maximum six months old)\n* urine-albumin\u002Fcreatinine-ratio (uACR) \\> 700 mg\u002Fg or 24 hours urine albumin \\>700 mg on more than one measurement\n\nExclusion Criteria:\n\n* Signs of acute kidney failure according to the KDIGO classification (21) at the time for kidney biopsy or the last 6 months before kidney biopsy\n* Factors that increases the risk of complications due to kidney biopsy:\n\n  * Hemoglobin \\\u003C 6 mmol\u002FL\n  * INR \\>1,4 at the time for biopsy\n  * Platelet count \\\u003C 100 x 109\u002Fl\n  * Uncontrolled high blood pressure (defined as systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg)\n  * Only one functioning kidney\n  * Evidence of urinary tract obstruction or hydronephrosis at the time of biopsy\n  * Multiple bilateral kidney cysts\n  * Kidney infection, peri-renal infection, or cutaneous infection that overlies the kidney at time for biopsy\n  * Unwilling to receive blood transfusion\n  * Unable to lie flat in bed six hours after biopsy\n  * Any other contra-indications for percutaneous kidney biopsy according to local clinical guidelines\n* Unable to understand written and oral information\n* Kidney transplant recipient\n* Previous medical kidney biopsy\n* Women who are pregnant or planning to become pregnant before the kidney biopsy is performed\n* Treatment with Marcoumar (all other anticoagulants are accepted)\n* High thromboembolic risk combined with held in anticoagulation therapy according to the report \"Perioperative regulation of antithrombotic treatment\" (PRAB) (22)\n\n  * mechanical heart valve\n  * atrial fibrillation AND CHA2DS2-VASc\\> 5 and\u002For stroke within the last three months\n  * recurrent venous thromboembolism OR venous thromboembolism within the last three months\n  * less than 6 weeks after uncomplicated Acute Coronary Syndrome (ACS) with or without revascularization (Percutaneous Coronary Intervention (PCI)) with Bare Metal Stents (BMS) or Coronary Artery Bypass Grafting (CABG))\n  * less than 3 months after uncomplicated ACS with revascularization (PCI with Drug Eluting Stent (DES))\n  * less than 9-12 months after complicated ACS (e.g. reinfarction or stent thrombosis)\n  * less than 1 month after revascularization in individuals with stable Coronary Artery Disease (CAD) (PCI with BMS or CABG)\n  * less than 3 months after revascularization in individuals with stable CAD (PCI with DES)\n  * less than 3 months after stroke, or Transient Ischemic Attack (TIA)\n* Inability to withdraw nonsteroidal anti-inflammatory drugs (NSAID) 7 days before biopsy\n\nIf a participant meets one or more exclusion criteria, that are reversible, the participant can be rescreened later on, to evaluate whether or not the participant now is qualified for participation.","120 Years",{"count":54,"type":21},300,"OBSERVATIONAL","a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.",[58,59,60,61,28,62,63],"Chronic Kidney Diseases","Albuminuria","Diabetic Kidney Disease","Diabetic Nephropathies","Molecular Sequence Variation","Kidney Biopsy",[65,66,67],"diabetic nephropaty","precision medicine","kidney biopsy","2025-12-17",{"date":70,"type":35},"2025-12-24",{"date":72,"type":35},"2021-08-10",{"date":74,"type":21},"2043-12-31",{"name":76,"class":42},"Herlev Hospital",13,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100430048","digital-individualized-and-collaborative-treatment-of-t2d-in-general-practice-based-on-decision-aid-100430048","NCT04880005","Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid","Protocol for the Digital, Individualized, and Collaborative Treatment of Type 2 Diabetes in General Practice Based on Decision Aid (DICTA) - A Randomized Controlled Trial","DICTA","Inclusion Criteria:\n\n* Diabetes type 2 in up to 10 years\n\nExclusion Criteria:\n\n* Fails to complete the initial questionnaire\n* No Internet access in own home through computer or smart phone\n* Is pregnant or actively trying to get pregnant\n* Has a serious or life-threatening disease","80 Years",{"count":88,"type":21},400,[24],"The purpose of this project is to improve life of patients with type 2 diabetes through an IT-supported lifestyle and treatment intervention.\n\nThe intervention is based on combining and adapting existing and effective elements into the IT system of the general practitioner. In this way we will integrate specialist supervised treatment in general practice, individual patient coaching, and improved information exchange and data mining.\n\nThe DICTA intervention consists of two integrated components: a patient-directed eHealth lifestyle coaching program delivered via the LIVA application, and a clinician-directed CDS tool embedded into the EPJ system.\n\n1. eHealth lifestyle coaching: Individuals with T2D in the intervention group will receive individualized digital coaching from a health coach through the LIVA application. PROs are shared with GPs and health staff via the EPJ, enabling tailored, data-driven lifestyle support.\n2. CDS: GPs receive real-time, individualized, algorithm-based pharmacological treatment recommendations for managing T2D, hypertension, and hypercholesterolemia, as appropriate.\n\nThis is expected to facilitate use, assure individually tailored solutions, optimize treatment effects, and strengthen patient engagement.\n\nThe study is a randomized controlled trial (RCT). It will include 400 patients with newly diagnosed type 2 diabetes. The patients will receive either treatment based on the intervention or usual care. After one year, we will assess quality of life and cardiovascular risk factors in both groups and evaluate if one group has improved management of their type 2 diabetes compared to the other.\n\nIf the intervention proves effective, implementation on a national scale is highly feasible, and the intervention could probably be adapted to other lifestyle-related chronic diseases in Denmark and in other countries.",[28],[93,94,95,96,97,98,99,100],"diabetes type 2 management","digital behavioral coaching","lifestyle change","health behavior change","weight loss","interactive advice","participant engagement","quality of life","2025-08-25",{"date":103,"type":35},"2025-09-02",{"date":105,"type":35},"2021-06-01",{"date":107,"type":21},"2025-12-30",{"name":109,"class":42},"University of Southern Denmark",1,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":139},"100370309","reset-system-pivotal-trial-rev-f-100370309","NCT04101669","RESET System Pivotal Trial (Rev F)","A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity","STEP-1","Inclusion Criteria:\n\n1. Age ≥22 years and ≤ 65 years\n2. Have understood and signed the approved informed consent form\n3. Diagnosis of type 2 diabetes\n4. HbA1c ≥ 7.5% and ≤10%\n5. BMI ≥30kg\u002Fm2 and ≤ 50kg\u002Fm2\n6. Willing and able to comply with study requirements\n7. Documented negative pregnancy test in women of childbearing potential\n8. Women of childbearing potential not intending to become pregnant (continue to be on an approved form of birth control) for the duration of their trial participation, including post explant period. Women of child-bearing age without known sterilization will be placed on 1 form of birth-control to prevent unwanted pregnancies\n9. At least one year of medical records available, including detailed medical therapy and dosing information\n10. Failed to achieve adequate HbA1c reduction (\\\u003C7.5%) after dual therapy for at least 3-month stable dosage of diabetes medication(s), including insulin, metformin, SGLT-2 inhibitor, GLP-1 RA, Dual GLP-1\u002FGIPR agonist or, other medications including meglitinides, sulfonylureas, thiazolidinediones, or DPP-4s.\n\nExclusion Criteria:\n\n1. Previous treatment with the RESET System\n2. Previous GI surgery that could preclude the ability to place the RESET Liner or affect the function of the RESET Liner, or abnormal GI anatomical finding that could preclude the ability to place the RESET Liner or affect the function of the RESET Liner\n3. Hypoglycemia and\u002For DKA\u002FHHNK in the last 6 months requiring 3rd party assistance\n4. Known history of liver disease (e.g., viral or autoimmune etiology, METAVIR grade 2 or higher fibrosis\u002Fcirrhosis from a biopsy within the past 6 months, but not including incidental fatty liver)\n5. eGFR of less than 45 ml\u002Fmin\u002F1.73 m2\n6. Prior history of an abscess requiring hospitalization, intravenous antibiotics or drainage\n7. Previous treatment for severe liver disease and\u002For biliary tract disease, including but not limited to, surgery, bile duct dilatation, and stent placement\n8. Diagnosis of type 1 diabetes mellitus or having any history of ketoacidosis\n9. Fasting C-peptide \\\u003C 1.0 ng\u002FmL\n10. Triglyceride level \\> 600 mg\u002FdL\n11. Vitamin D deficiency (\\\u003C20ng\u002Fml)\n12. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000\u002Fmicroliter, or known coagulopathy\n13. Height \\\u003C 5 feet (152.4 cm)\n14. Current alcohol addiction, current drug addiction or usage, of drugs such as, narcotics, opiates, or benzodiazepines and other addictive tranquilizers\n15. History of pancreatitis, including gallstone related pancreatitis (subsequent to which patient has cholecystectomy)\n16. Diagnosis of osteopenia or osteoporosis or currently taking denosumab, romosozumab-aqqg, bisphosphonates or teriparatide\n17. Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma)\n18. Active or recent (less than 12 months) gastroesophageal reflux disease (GERD) unless treated with H2RAs not PPI.\n19. Uncontrolled thyroid disease, including a history of thyroid cancer, hyperthyroidism, or taking thyroid hormone for any reason other than primary hypothyroidism (TSH level must be between 0.4-4)\n20. Currently taking prescription antithrombotic therapy (e.g. anticoagulant or antiplatelet agent) within 10 days prior to randomization and\u002For there is a need or expected need to use during the trial 9 months post implant procedure\n21. Currently taking the following medications (within 30 days prior to randomization) and\u002For there is a need or expected need to use these medications during the trial 12 months post index procedure:\n\n    Restricted Medications\u002FSupplements Systemic corticosteroids Proton Pump Inhibitor (PPI) Drugs known to affect GI motility (e.g.metoclopramide) Prescription or over-the-counter weight loss medication(s) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), aspirin, ibuprofen, and other anti-inflammatory medication for study duration Medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics)\n\n    Supplements that are known or suspected to increase bleeding risk including but not limited to:\n\n    Gingko biloba Ginseng Vitamins C \\& E Turmeric St. John's wort Evening primrose oil Feverfew Green Tea Extract\n22. Active H. pylori\n23. History of Crohn's disease, atresias or untreated stenoses\n24. Abnormal pathologies or conditions of the gastrointestinal tract, including ulcers or upper gastrointestinal bleeding conditions within 3 months of randomization\n25. Patients may be disqualified for study inclusion for any condition determined by the PI that places the patient at undue risk\n26. Poor dentition not allowing complete chewing of food\n27. Enrolled in another investigational study within 3 months of screening for this study (enrollment in observational studies is permitted)\n28. Residing in a location without ready access to study site medical resources\n29. Documented weight loss of 5% total body weight (TBW) anytime during the 3 months preceding randomization\n30. Positive Fecal Immunochemical Test (FIT) at time of screening\n31. History or observation of psychological disorder or behavior which could preclude compliance to the treatment and follow up plan\n32. No access to an active telephone and internet service for provision of Follow Up Schedule calls and electronic diary\n33. Having donated blood or received a blood transfusion in the 90 days prior to baseline labs. Patients should agree not to donate blood during the study\n34. Any condition that increases red cell turnover, such as thalassemia\n35. Existence of (\\>5 cm string test) Pseudomonas aeruginosa, Stenotrophomonas maltophilia and\u002For Klebsiella pneumoniae serotype K1 and K2\n36. A known sensitivity to nickel or titanium\n37. Do not meet the screening criteria for MRI (i.e., MRI unsafe, or MRI conditional but not appropriate for the region of interest)\n38. Patients with history or suspicion of coronary artery disease","22 Years","65 Years",{"count":122,"type":21},264,[24],"A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study.\n\nA multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System plus moderate intensity lifestyle and dietary counseling compliant with 2024 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will practice medical management compliant with STEP-1 Study Guidelines. Patients will be randomized 3 (RESET):1 (Sham).",[28,126],"Obesity",[128,126],"Type 2 Diabetes","2024-07-16",{"date":131,"type":35},"2024-07-18",{"date":133,"type":35},"2019-09-09",{"date":135,"type":21},"2026-12-01",{"name":137,"class":138},"Morphic Medical Inc.","INDUSTRY",7,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":110},"100439143","impact-of-obesity-chronic-kidney-disease-and-type-2-diabetes-on-human-urinary-stem-cells-100439143","NCT04998461","Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells","URISTEM","Inclusion Criteria - For all participants :\n\n* Age between 18 and 60\n* Non diabetic (fasting blood glucose \\\u003C1.26 g\u002FL)\n* Patient not having objected to participating in the research\n\nInclusion Criteria - For the obese group with normal renal function\n\n* eDFG ≥ 60 ml\u002Fmin\u002F1.73 m2\n* BMI \\> 30 kg\u002Fm2\n* Microalbuminuria \u002F creatinuria ≤ 3mg \u002F mmol and \u002F or proteinuria \\\u003C 0.15 g\u002F24h\n\nInclusion Criteria - For the obese group with impaired renal function\n\n* eDFG \\\u003C 60 ml\u002Fmin\u002F1.73 m2\n* BMI \\> 30 kg\u002Fm2\n* Microalbuminuria \u002F creatinuria ≤ 3mg \u002F mmol and \u002F or proteinuria \\\u003C 0.15 g\u002F24h\n\nInclusion Criteria - For the non-obese group with impaired renal function\n\n* eDFG \\\u003C 60 ml\u002Fmin\u002F1.73 m2\n* BMI between 18 and 30 kg\u002Fm2\n* Microalbuminuria \u002F creatinuria ≤ 3mg \u002F mmol and \u002F or proteinuria \\\u003C 0.15 g\u002F24h\n\nInclusion Criteria - For the non-obese group with normal renal function (control group)\n\n* eDFG ≥ 60 ml\u002Fmin\u002F1.73 m2\n* BMI between 18 and 30 kg\u002Fm2\n* Microalbuminuria \u002F creatinuria ≤ 3mg \u002F mmol and \u002F or proteinuria \\\u003C 0.15 g\u002F24h\n\nExclusion Criteria - For all participants :\n\n* Acute renal failure within 3 months (defined as an increase of more than 50% in usual creatinemia)\n* Inflammatory, infectious, cardiovascular or progressive neoplastic disease\n* Urinary pathology (malformation, infection, etc.)\n* Exclusion period of a previous study or already participating in a clinical research protocol having an impact on the judgment criteria of the study","60 Years",{"count":149,"type":21},60,"Obesity is at risk for the development of chronic kidney disease but the involved mechanisms are not known (Navarro et al. 2015). Establishing the link between obesity and kidney damage is difficult. Indeed, kidney function measurement lacks precision in obese people (Lemoine et al. 2014) and requires expensive methods such as measurement of 99mTc-DTPA clearance. Biopsies are too invasive for the detection of emerging kidney damage or for the following of the kidney function. Therefore new tools are required for the early identification of at risk individuals for the kidney damage complication.\n\nMesenchymal stem cells may represent such a relevant tool. These cells are present in a large number of organs, including kidney (Costa et al. 2020).\n\nIn addition to be differentiated cells progenitors (Dominici et al. 2006), they also support immunosuppressive, anti-fibrotic and pro-angiogenic functions that have been used for the treatment of kidney fibrosis (Usunier et al. 2014). Therefore, mesenchymal stem cells contribute to tissue homeostasis and their alterations may reflect organ dysfunctions. Indeed, mesenchymal stem cells from obese adipose tissue lose their immunosuppressive (Serena et al. 2016) and differentiation (Gustafson et al. 2009) functions and contribute to fibrosis (Keophiphath et al. 2009) and inflammation (Lee et al. 2010; Gustafson, Nerstedt, et Smith 2019). It is thus probable that kidney dysfunctions are associated with functional alterations of kidney mesenchymal stem cells.\n\nThe collection of mesenchymal stem cells from kidney can easily be performed from urine and next cultivated for amplification. They are called urine stem cells (USC).\n\nFrom our experience with obese mouse adipose stem cells, we observed that functional changes of stem cells preceded adipose tissue dysfunctions. Functional signatures of mesenchymal stem cells are thus representative of changes occuring in the function of the tissue notably in answer to obesity. These features could be used to identify obese people presenting ongoing alterations of kidney function, before clinical manifestations of kidney dysfunction. Because kidney mesenchymal stem cells are easy to isolate from urine, their collection is compatible with the follow up of patients and can be applied to a large number of individuals, including the younger. USC could represent a valuable tool to detect progression towards kidney damage.\n\nIn this project we plan to analyse USC alterations induced by obesity and to identify signatures associated with the progression towards kidney damage and type 2 diabetes. The goal is to evaluate USC as potential marker for the non invasive monitoring of patients in answer to a need that is not achieved by the present available approaches.",[58,126,152,28],"Stem Cells",[154,58,126,28],"bio-marker","NOT_YET_RECRUITING","2021-08-02",{"date":72,"type":35},{"date":159,"type":21},"2021-11",{"date":161,"type":21},"2026-06",{"name":163,"class":42},"Hospices Civils de Lyon"]